Skip to main content

Open Orphan Share Forecast, Price & News

GBX 35.50
+0.55 (+1.57 %)
(As of 05/14/2021 04:35 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume2.46 million shs
Average Volume3.22 million shs
Market Capitalization£237.64 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ORPH News and Ratings via Email

Sign-up to receive the latest news and ratings for Open Orphan and its competitors with MarketBeat's FREE daily newsletter.

About Open Orphan

Open Orphan plc operates as a clinical research organization pharmaceutical services company with a focus on virology, vaccine studies, and orphan drugs in the United Kingdom, Ireland, France, the Netherlands, Germany, and Singapore. It operates a virtual rep, a pharmaceutical commercialization platform for rare/orphan disease space; and develops Genomic Health Data platform, a collection of infectious disease progression data. The company also provides consulting and clinical trial services to pharmaceutical, biotechnology, and medical device organizations. In addition, it offers hVIVO COVID Clear Test, an antibody test for employers in the United Kingdom and Ireland. The company is headquartered in London, the United Kingdom.


See More Headlines

Industry, Sector and Symbol

Industry Biotechnology
Phone353 1 644 0007
Year FoundedN/A

Sales & Book Value

Annual Sales£10.57 million
Cash FlowGBX 3.17 per share
Book ValueGBX 6 per share





Market Cap£237.64 million
Next Earnings Date6/21/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

0.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Open Orphan (LON:ORPH) Frequently Asked Questions

What stocks does MarketBeat like better than Open Orphan?

Wall Street analysts have given Open Orphan a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Open Orphan wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Open Orphan's next earnings date?

Open Orphan is scheduled to release its next quarterly earnings announcement on Monday, June 21st 2021.
View our earnings forecast for Open Orphan

Who are Open Orphan's key executives?

Open Orphan's management team includes the following people:
  • Mr. Cathal Martin Friel, Exec. Chairman (Age 56)
  • Dr. Trevor Michael Phillips, Chief Exec. Officer (Age 60)
  • Mr. Leo Toole, Group CFO & Director (Age 48)
  • Mr. Timothy Sharpington, Chief Operating Officer (Age 55)
  • Dr. Maurice N. Treacy, Chief Commercial Officer

Who are some of Open Orphan's key competitors?

What is Open Orphan's stock symbol?

Open Orphan trades on the London Stock Exchange (LON) under the ticker symbol "ORPH."

How do I buy shares of Open Orphan?

Shares of ORPH and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Open Orphan's stock price today?

One share of ORPH stock can currently be purchased for approximately GBX 35.50.

How much money does Open Orphan make?

Open Orphan has a market capitalization of £237.64 million and generates £10.57 million in revenue each year.

How many employees does Open Orphan have?

Open Orphan employs 132 workers across the globe.

What is Open Orphan's official website?

The official website for Open Orphan is

How can I contact Open Orphan?

The company can be reached via phone at 353 1 644 0007.

This page was last updated on 5/14/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.